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1. Introduction 
1.1 ErbB receptors, ligands and signaling 
Breast cancer affects nearly 1 out of 9 women worldwide. The quality of treatment for breast 
cancer has improved to the point that close to 80% of patients in countries with advanced 
healthcare delivery systems survive the disease (1). Yet over 20% of breast cancer patients 
succumb to the disease, and the majority of these have metastatic breast cancer cells that 
occupy and compromise the function of distal organs (1). There has been an intensive effort 
to improve treatments for metastatic breast cancer. Novel treatment strategies have arisen 
from the study of the molecular and cellular biology of breast cancer cell lines. These studies 
have produced a group of agents called targeted therapeutics because they are often 
directed at a single molecule rather than a general process such as DNA replication or 
cytoskeletal function. The ErbB family represents a target that is present in breast cancer. 
Therapeutics to ErbB2 have been used to treat aggressive breast cancer for over a decade 
with considerable success (2). However, therapeutics that primarily target the EGFR have 
not been used extensively in breast cancer, and there are some improved agents for the 
receptor that are just entering the clinic. Recent conclusions from studies of metastatic breast 
cancer suggest new possibilities for the use of EGFR therapeutics. This review will describe 
the members of the EGFR signaling family, discuss the cellular context in which they 
function in development, and correlate this with the biological role of these molecules in 
breast cancer metastasis.  
1.2 ErbB family members 
The ErbB family consists of 4 receptors: ErbB1 or more commonly called EGFR, ErbB2/ 
Her2, ErbB3 and ErbB4 (3). Signaling is generated when EGFR and ErbB4 bind to their 
ligands. In contrast, the ErbB2 extracellular binding domain fails to bind any of the 15 
agonists, and in ErbB3 the kinase domain is not functional. Upon ligand stimulation, EGFR 
and ErbB4 receptors can transduce their signals as homodimers or heterodimers; however, 
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the signal generation from ErbB2 or ErbB3 require heterodimerization with another ErbB 
family member (3).  
The ErbB receptors are stimulated by 15 ligands but the situation is complicated because 
several of these agonists can bind more than one receptor. The EGFR exclusive agonists are 
epidermal growth factor (EGF), transforming growth factor alpha (TGF-), amphiregulin 
(AREG) and Epigen (Epi) (3, 4). ErbB4 is specifically bound and activated by Neuregulins 
(NRG) 3, 4, 5 (3, 4). Heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EREG), 
and -cellulin (BTC) bind and activate both the EGFR and ErbB4 (3, 4). NRG 1 and 2 binds 
both ErbB3 and ErbB4 and NRG 1 can bind the EGFR with low affinity (3, 4).  
All of the ErbB agonists are synthesized as plasma membrane bound integral membrane 
proteins (5). In some cases, the transmembrane ligands stimulate ErbB signaling on adjacent 
cells through a juxtracrine mechanism which may mediate the stromal-epithelial 
interactions (6) (7). Most ErbB signaling requires proteolytic cleavage termed ectodomain 
shedding for the ligand to be released and available to bind receptors that may be on the 
same cell (autocrine signaling), or on neighboring cells (paracrine signaling) (5). The 
proteases that mediate the process are from the “a disintegrin and metalloproteinase “ or 
(ADAM) family (8, 9). There are 40 members of the ADAM protein family that function in 
cell adhesion and ectodomain shedding. These ADAMs are integral membrane proteins in 
which the extracellular region contains a protease as well as a disintegrin domain that 
modulates integrin binding (9). ADAMs can be activated by a wide range of stimuli that 
signal through G-protein-coupled receptors and these signals are often transduced by Src 
(10). The shedding of AREG, EREG, HB-EGF, Epigen, TGF and NRG 1&2 is typically 
catalyzed by the single family member ADAM 17, whereas BTC and EGF are cleaved by 
ADAM 10 (8). In addition, ADAM 17 cleaves many other cytokines, growth factors, 
receptors, adhesion molecules and extracellular matrix proteins, suggesting its activity may 
be a key determinate of cellular behavior (9). Nevertheless, emerging data suggest that 
EGFR ligands can be shed by other proteases such as the ADAM thrombospondin 
(ADAMTS) family that is structurally related to the ADAM family, but is secreted and the 
disintgrin domain is replaced by a thrombospondin domain that binds to matrix (11, 12). 
Also, it is likely that other metalloproteinases secreted from cells in a paracrine relationship 
are capable of releasing ligands (13). 
Over the past two decades the expression of ErbB receptors, ligands, and their activating 
proteases in normal breast and breast cancers have been intensively studied. Various mRNA 
detection methods and immunohistochemistry studies have concluded that the entire ErbB 
family is expressed in various breast cancers. In fact, it appears the vast majority of the 
family is expressed in the mammary epithelia (14-16). Since newer therapeutics that target 
the EGFR are being considered for use in cases of advanced breast cancer, in the rest of this 
review we will focus on how this receptor is activated and describe its role in development 
and cancer progression. 
1.3 EGFR homodimer signaling 
EGF was the first ligand identified and due its abundance in the mouse salivary gland and 
relative ease of purification from this source (17). EGF has historically been used for receptor 
binding, signaling, trafficking, and cell fate studies resulting in a model of receptor signaling 
that is in many ways considered to be the prototype for receptor tyrosine kinases (18-20). 
The binding of EGF to the EGFR exposes the dimerization arm in the extracellular domain 
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that permits interaction with another EGFR receptor or hetrodimerization with other ErbBs. 
Ligand binding also induces a conformational change in the receptor that activates the 
intracellular kinase domain, which in turn can phosphorylate tyrosine residues on the 
adjacent C-terminal tail of the dimerized ErbB receptor. The 10 phosphorylated tyrosine 
residues serve as docking sites for adapter proteins or other signal transduction 
components, resulting in activation of Ras, MAPK, src, STAT 3/5 and PLC/PKC and the 
PI3 kinase-AKT-pro survival pathway. Activation of these signaling pathways by ErbB 
dimers has profound impact on proliferation, resistance to apoptosis, differentiation, as well 
as motility/migration associated behaviors. Not all tyrosine phosphorylation of EGFR C-
terminal tail results in stimulation of downstream signaling pathways. For example, 
phosphorylation of the 974 residue triggers enodcytosis of the receptor, and phospho 1045 
binds to Cbl, mediating ubquitination of the receptor and subsequent proteosomal 
degradation (4, 21). Trafficking studies suggest that ~50% of EGF stimulated EGFR is 
degraded, whereas the remainder is recycled back to the plasma membrane (22). Thus, 
activation of the EGFR by EGF directly stimulates a broad group of cellular signaling 
pathways, many of which converge on elements of the ERK/MAPK pathway (3), but this 
signaling is dampened by receptor turnover. The rapid turnover of the EGF stimulated 
EGFR is believed to limit stimulation of cellular proliferation, permitting a balance with 
various differentiation-inducing stimuli present in a normal tissue (3, 22, 23). In cancers, 
autocrine EGFR homodimer signaling is substantially attenuated, shifting the cell fate 
balance towards proliferation and survival rather than differentiation, apoptosis and 
senescence.  
1.4 Attenuating EGFR signaling with heterodimerization 
Probably the most well understood attenuation of EGFR signaling occurs when the receptor 
heterodimerizes with the ErbB 2 receptor (24, 25). It is believed that EGFR heterodimerization 
with ErbB2 frequently occurs in a number of breast cancers (26, 27). Despite being unable to 
bind ligand, the ErbB2 dimerization arm is constitutively exposed, which allows this receptor 
to more efficiently dimerize with other liganded ErbB family members (4). The resulting 
ErbB2 containing heterodimers attenuate EGFR signal transduction in several ways (28-32). 
First, the affinity of this ErbB2 complex for ligands is enhanced. Second, the ErbB2 
phosphotyrosine domains bind most adapter proteins with higher affinity than those of the 
ErbB homodimers, resulting in more efficient signal transduction. Third, ErbB2/EGFR 
heterodimers are slowly endocytosed, and are more frequently recycled to the plasma 
membrane than the EGF stimulated homodimers. By virtue of its strong interactions with 
adapter proteins and altered trafficking downstream of endocytosis, an EGFR/ErbB2 
heterodimer can amplify and extend the duration of EGFR ligand signaling, leading to 
proliferation and survival at the expense of other cell fates (28-31).  
In contrast to the fairly well established understanding of ErbB2 containing heterodimers, 
there have been few studies on the EGFR heterodimerized with ErbB4 or ErbB3. Co-immuno 
precipitation experiments have confirmed the presence of the ErbB4/EGFR in a lung 
epithelial cells and type II pneumocytes; however, the specific function of this complex was 
not determined (33, 34). Co-expression of ErbB4 and EGFR plasmids in model NIH 3T3 
fibroblasts or CHO lines, provided evidence of dimerization of these receptors, and 
suggested that this complex could induce cellular transformation in the presence of EGF or 
NRG1. Further analysis of the CHO system found that the ErbB4/EGFR heterodimer 
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specifically induced B-Raf kinase activity, which was speculated to induce transformation 
by increasing the activity of the ERK/MAPK pathway (35). Recently, ErbB3/EGFR 
heterodimers have been identified in pancreatic cancer cell lines (36, 37). It appeared that the 
ErbB3/EGFR complex may be a more effective stimulus of proliferation in pancreatic cancer 
cell lines than EGFR homodimers (36). Additionally, these studies suggest the ligand AREG 
is able to stimulate activity of the ErbB3/EGFR heterodimer (36, 37). Unfortunately, the 
comprehensive binding, signal transduction and trafficking studies completed for ErbB2 
containing receptor complexes have not been completed for EGFR/ErbB4 or ErbB3 
heterodimers. This information, coupled with the identification of the specific cell types and 
tumors that express heterodimers and the function of these complexes will be important 
considerations for expanded use of ErbB targeted therapeutics.  
1.5 Other EGFR ligands 
As studies of receptor binding, conformation, phosphorylation, and trafficking are 
completed for each ligand, it is becoming clear that each agonist induces signaling that can 
be viewed as a variation of the basic EGF-EGFR homodimer scenario. This attenuated 
signaling produced by each ligand has the potential to induce subtle differences in 
downstream signaling, which would be expected to result in altered gene expression and 
cellular behavior. In the preceding section, the emerging differences in signaling are detailed 
for each of the ligands that bind the EGFR.  
1.5.1 TGF 
Next to EGF, the most intensively studied ligand has been TGF. Similar to EGF, TGF 
exclusively binds to and activates the EGFR. Binding studies suggest that TGF binds to 
the receptor with similar affinity as EGF (32). However, conclusions from structural studies 
involving ligand-receptor complex data indicates there are subtle differences in the 
conformation of the extracellular ligand-binding domain (sub domain II) induced by TGF 
as compared to EGF (4). It is unclear whether this conformational change induced by TGF 
could generate alterations in EGFR kinase activity or accessibility of C-terminal tyrosines. 
Although not comprehensively studied at this point, some of our early studies with breast 
cancer cell lines suggest that TGF does not induce the extensive receptor phosphorylation 
observed with mouse salivary gland derived EGF (Fig 1). Additionally, it has been long 
recognized that TGF induces different trafficking of the receptor than EGF (38). Close to 
100% of receptors internalized after TGF treatment are recycled to the plasma membrane 
(22). At physiological pH of 7.4 in the extracellular environment, TGF and EGF have 
similar binding affinities for the EGFR (22, 38). However, at pH close to 5 such as in the 
endosome, TGF has decreased affinity for the EGFR (22, 38). It appears that dissociation 
of the ligand from the EGFR in the endosome permits the receptor to be recycled back to 
the plasma membrane where it can be reengaged by ligand. It is thought that the three 
additional histidines found in the receptor binding domain of TGF provide a greater 
sensitivity to pH for agonist-receptor interactions (38). In fact, mutations that add 
histidines to this region of EGF decreased ligand-receptor binding at low pH (39, 40). 
Together, the altered ligand induced receptor conformation, phosphorylation and 
trafficking appear to result in TGF being a more potent stimulator of proliferation of 
EGFR expressing cell lines than EGF. 
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Fig. 1. EGFR phosphorylation after ligand stimulation. 
The human breast cancer cell line MCF7 was engineered to overexpress high levels of the 
EGFR after retroviral transduction. Cells were grown to 80% confluence and placed on ice 
for 30 minutes. Ligands (R&D, Minneapolis) were applied for 10 minutes to the media and 
then the media was removed, cells washed and proteins extracted. The EGFR was 
concentrated with Concanavalin A beads and extracted with Laemmli sample and applied 
to gels and western blotted with specific antibodies to phosphorylated tyrosines listed on 
the left. The various ligands used are listed on the top of the figure (C) represents vehicle 
treated cells.  
1.5.2 AREG  
The differential impact on breast cancer cell behavior that AREG exhibits compared to EGF 
has drawn considerable attention to the concept that various EGFR ligands have discrete 
functions (41-43). Among the ErbB receptors, AREG appears to exclusively bind and activate 
the EGFR. In addition, the ligand contains a heparin-binding domain N-terminal to the 
receptor binding region (44, 45). It appears that interaction with heparin-sulfated 
proteoglycans on the plasma membrane enhances the ability of exogenous AREG to activate 
the EGFR (46). What has been a matter of controversy has been the relative strength of 
AREG binding to the EGFR as compared to other ligands. The initial identification of human 
AREG by Shoyab and colleagues, reported the fully processed ligand isolated from breast 
cancer cells had reduced affinity for the human EGFR, as compared to salivary gland 
derived mouse EGF (44). In contrast, subsequent studies with human recombinant ligands 
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found that AREG has similar affinity for the EGFR as EGF and TGF (47, 48). Inducing 
further complexity, additional analyses of ligand receptor interactions have suggested that 
recombinant AREG does not induce efficient dimerization of the EGFR, as compared to 
recombinant EGF and TGF (49). Interestingly, proteolytic processing of AREG in 
mammalian cells may eliminate the C-terminal portion of the ligand binding domain that is 
required for high affinity for the receptor (50). In addition, the terminal portion of the 
receptor binding domain in all other EGFR ligands contains a leucine, whereas a methionine 
is found in AREG, and this is speculated to reduce affinity for the receptor (50).  
More recent studies have focused on the distinct downstream signaling and cellular 
behavior induced by AREG. Unlike exogenous EGF treatment, AREG stimulation of model 
cell lines and breast cancer cell lines is unable to induce efficient phosphorylation of many of 
the tyrosine residues in the C-terminal tail of the EGFR (22, 43, 51, 52) and (Fig. 1). Notably, 
the Cbl binding 1045 tyrosine residue is not efficiently phosphorylated by AREG and this 
ligand fails to induce rapid turnover of the EGFR. Trafficking studies indicate that AREG 
liganded EGFR is rapidly internalized, but then is recycled back to the plasma membrane. In 
addition, AREG binding to the EGFR is very resistant to acidic pH suggesting that the 
ligand does not disengage in the endosome as does TGF (22). It appears that AREG may be 
unique among the ligands in that it induces EGFR trafficking through Rab 4 and Rab 11 
containing endosomes (22, 43). AREG induces prolonged phosphorylation of ERK relative to 
EGF (41, 52). This altered signaling appears to be the basis of AREG stimulating the loss of 
cell-cell adhesion and increase motility/migration associated behaviors in breast and other 
epithelial cells (41, 53). AREG overexpression has also been found to selectively activate 
interleuken-1 induced NF signaling in breast epithelial cells (41-43).  
1.5.3 Epigen 
This was the last ErbB family member identified in 2000, and it has not been as intensively 
studied as other ligands. The ligand activates the EGFR and does not activate ErbB3 or 
ErbB4 when these receptors are expressed in isolation (54, 55). However, epigen can activate 
ErbB4 and ErbB3 when these receptors are co-expressed with ErbB2 (54, 55). Epigen appears 
to have ~100 fold less affinity for the EGFR relative to recombinant human EGF. Not 
surprisingly, we found that epigen induced modest phosphorylation of breast cancer cells 
(Fig. 1). The binding of epigen to the EGFR appears to be sensitive to pH similar to TGF. 
Modeling suggests that additional histidines in the receptor binding domain are responsible 
for the dissociation of the ligand from the EGFR at low pH (54, 55). In comparison with EGF, 
epigen induced significantly weaker ubiquitylation and degradation of EGFR, and once 
internalized, it appears that the receptor is efficiently recycled to the plasma membrane. As 
expected for lower affinity ligands, epigen is a more potent mitogen than EGF and displays 
prolonged MAPK signaling (54, 55). 
1.5.4 HB-EGF 
Exogenous HB-EGF is a high affinity ligand for the EGFR but it also binds and activates 
ErbB4 (32). Exogenous HB-EGF does not as robustly stimulate phosphorylation of ErbB4 as 
it does the EGFR (56). In addition, pro-HB-EGF serves as the diptheria toxin receptor in 
human cells (6). Similar to EGF, exogenous HB-EGF induces extensive EGFR tyrosine 
phosphorylation in most cell types studied (22, 56), and we found this to be the case for 
breast cancer cells (Fig. 1). Upon binding to and activation by HB-EGF, the EGFR is rapidly 
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endocytosed and the majority of ligand engaged receptors are trafficked to lysosomes and 
degraded (22). The binding of HB-EGF to the EGFR was resistant to low pH. HB-EGF shows 
similar effects on cell proliferation and migration to those exhibited by EGF (57).  
As its name implies, HB-EGF has a heparin-binding region N-terminal to the EGF domain. 
This domain has been shown to interact with heparin sulfated plasma membrane proteins 
such as the tetraspanin, CD9 and the extracellular matrix binding/cell differentiation 
marker protein CD44 (6, 57). In particular the heparin-mediated interaction between HB-
EGF and CD9 appear to be crucial to juxtacrine signaling by the proligand (58). Finally, the 
associations between the heparin binding domain and cell membrane associated heparin 
sulfated proteoglycans appear to be crucial to localizing HB-EGF to regions of cell-cell 
contact. Furthermore, the interaction with these heparin-sulfated proteoglycans prevented 
proteolytic cleavage of the pro-ligand, whereas exogenous heparin increased shedding of 
HB-EGF (7, 58). In contrast to the impact of shed ligand, juxtacrine signaling by the pro HB-
EGF appears to be antiproliferative (58). 
1.5.5 -cellulin 
Exogenous -cellulin is a high affinity ligand for the EGFR and ErbB4 (32). In general, 
exogenous -cellulin phosphorylates the EGFR to a similar extent as EGF in model cell 
types, and this is what we observed with breast cancer cells (Fig. 1) (22, 59). This exogenous 
ligand also stimulates total ErbB4 phosphorylation to an extent similar to NRG1, but there 
may be differences in phosphorylation of specific tyrosine residues (60). Upon binding to 
and activation by -cellulin, the EGFR is rapidly endocytosed and trafficked to lysosomes 
where the majority of it is degraded (22). The binding of -cellulin to the EGFR was resistant 
to low pH. Exogenous -cellulin was slightly less efficient than EGF at inducing 
proliferation in some specific cell types (60). There have been some reports that -cellulin 
binds to heparin and may participate in juxtacrine signaling (61). 
1.5.6 EREG 
Unlike the other dual receptor ligands HB-EGF and BTC, EREG is a low affinity ligand for 
the EGFR (32). EREG typically induces much less phosphorylation of the EGFR than EGF in 
model cell lines (62-65). In breast cancer cells, we found that the epiregulin induced 
phosphorylation of the various tyrosines on the EGFR to an extent similar to AREG and the 
low affinity ligand epigen (Fig. 1). EREG is not as effective as NRG or BTC in stimulating 
ErbB4 phosphorylation (62-65). The ligand appears to preferentially activate heterodimers 
and efficiently induces EGFR heterodimers with all three other receptors (65). Upon binding 
to and activation by EREG, the EGFR is rapidly endocytosed, but then is recycled back to the 
plasma membrane, and its binding to the receptor was resistant to low pH (22). Exogenous 
EREG was more efficient than EGF at inducing proliferation in some cell types (63, 65). Also 
EREG does not induce as great of activation of the MAPK pathway as EGF, but the duration 
of MAPK phosphorylation was increased relative to the prototype ligand (63, 65). 
Thus, the expression of specific EGFR ligands could influence the progression of breast 
cancer in several ways. First, three of the ligands (HB-EGF, BTC and EREG) could induce 
ErbB4 signaling on breast cancer cells themselves or their microenvironment, whereas the 
other 4 ligands EGF, TGF, AREG and epigen would only induce EGFR signaling. Second, if 
juxtacrine EGFR signaling between breast cancer cells may require interaction with heparin 
sulfate proteoglycans, only HB-EGF and AREG would be likely mediators of this signaling. 
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Juxacrine EGFR signaling might be antiproliferative and also only occur in breast cancer that 
lacked active sheddases that released HB-EGF and AREG. Third, EGFR signaling induced 
by soluble ligands appears to be dependent on the relative ratio of receptor degradation 
versus recycling to the plasma membrane. For example, those ligands whose binding leads 
to rapid receptor degradation (EGF, HB-EGF and BTC) would activate high levels of 
downstream signal transduction, but this would likely be of short duration. In contrast, the 
ligands that induce recycling of the internalized receptor to the plasma membrane would 
produce longer duration EGFR signaling. In the context of autocrine signaling in breast 
cancer cells, the longer duration EGFR signaling is likely to more efficiently induce 
mitogenesis. What remains to be determined is whether the duration of EGFR signaling 
differentially impacts other cellular behaviors relevant to breast cancer progression such as 
resistance to apoptosis, and the stimulation of invasive/motile behaviors. Finally, in the 
context of paracrine signaling it is not clear how EGFR turnover influences the supportive 
functions of stromal and immune cells of the tumor microenvironment.  
2. EGFR/ErbB signaling in development 
2.1 ErbB signaling and mammary gland development  
The majority of research on mammary gland development is performed in the mouse model 
due to its biologically and histologically similarity with humans, and the power of 
transgenic knockout murine models (66). Embryonic mammary gland development in the 
mouse begins around embryonic day 10.5 (E 10.5), where bilateral milk lines are formed 
from front to hind paws. Between E11.5 and E12.5, five placodes on each milk line develop 
with eventual epithelial bud formation at each placode. These epithelial buds remain 
quiescent until E15.5, where minor branching permits the migration of mammary epithelia 
into the fat pad, and mesenchymal differentiation forms the overlying nipple epidermis. 
This rudimentary mammary gland will remain quiescent until after birth (67). The majority 
of mammary gland growth and development occurs in postnatal life during puberty and 
pregnancy, and ErbB signaling impacts this phase.  
The primary hormone that drives post-natal mammary gland development is the nuclear 
steroid hormone, estrogen. Estrogen stimulates proliferation of luminal cells within the 
mammary ducts, causing ductal elongation and branching (68). Progesterone also increases 
cellular proliferation of the mammary ducts, and acts synergistically with estrogen during 
periods of high hormone levels such as pregnancy (68). Prolactin, a non-steroid hormone 
released from the pituitary gland, is active in mammary gland development, late in 
pregnancy, stimulating alveolar development and triggering milk production during 
lactation (69). 
The mouse mammary gland begins pubertal outgrowth between 3-4 weeks of age, and is 
complete at 8-12 weeks of age. The gland requires both longitudinal ductal growth, as well 
as ductal branching to fully infiltrate the mammary fat pad. Pubertal growth is directed by 
the cells within structures called terminal end buds (TEBs), which are a bulbous expansion 
of the epithelia. The TEBS are found at the distal end of each growing duct, and consist of 3 
to 4 cell layers, including cap cells that make up the ‘basal’ layer and multiple layers of 
interior luminal-like body cells that line the duct. Signaling within the cells of the TEBs and 
the surrounding stroma will determine the extent of continued ductal branching (70) (71). 
From this point, the mammary gland will show minimal growth with each estrous cycle. 
Upon pregnancy, estrogen and progesterone drive another large spurt of growth resulting 
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in extensive ductal branching. Progesterone also works with prolactin to signal 
differentiation of the secretory or alveolar cells throughout the duct system, which produces 
the large volumes of milk post parturition (72, 73). Termination of lactation will eventually 
lead to involution, where large-scale apoptosis will eliminate the secretory alveoli and 
remodel the remaining ducts of the mammary gland, returning the structure to a state 
similar to that of the virgin gland.  
2.1.1 Role of EGFR in mammary gland growth 
In virgin mice, EGFR, ErbB2, and ErbB3 are present in the developing ductal structure 
while there is minimal ErbB4. During pregnancy, this pattern changes to greatly increase 
expression of ErbB4 in the mammary epithelium, while ErbB4 levels will again regress 
during lactation and involution (74). Even though three of the receptors are present 
during growth, there is minimal ErbB phosphorylation observed until ductal 
morphogenesis begins. During pubertal growth, phosphorylated EGFR and ErbB2 are 
detected, which suggested that these receptors may mediate the impact of estradiol (E2) 
on the gland (75).  
The EGFR-/- mice die within 8-days after birth and show a wide range of dysfunctional 
epithelia, but their mammary glands were similar to their wild-type littermates. 
Transplantation of pre-pubertal glands from EGFR-/- mice into cleared fat pads of wild-type 
littermates failed to infiltrate the structure, but glands from wild-type mice produced 
normal ductal systems (76). In contrast, when a purified mammary epithelium from the 
EGFR-/- mouse was implanted into cleared fat pads with mammary stroma from wild-type 
mice it produced a normal ductal tree, whereas the opposite combination of wild-type 
epithelium and EGFR-/- stroma failed to penetrate the fat pad. Thus, postnatal mammary 
ductal growth is dependent on the presence of the EGFR in mammary stromal fibroblasts. It 
appears that signaling by the receptor triggers the production of stromal growth factors 
important to TEBs in ductal elongation (76).  
The EGFR ligands EGF, TGF, and AREG, are found in different locations within the TEB 
during ductal growth. Using immunohistochemical techniques, TGF is found exclusively 
in the basal cap cell layer while the luminal cells express only EGF (70). AREG has been 
found in both the basal cap cells and the luminal cell layers of TEBs (77). Luekette and 
colleagues produced knockout mice for each of these ligands separately or as double and 
triple knockouts. While all three mice null for the individual ligands and their various 
crosses were fertile, not all had distinct mammary phenotypes. Double-knockout mice for 
EGF and TGF, but which contained AREG, displayed normal ductal growth and TEB 
formation. Mice that were single-knockout for AREG or a triple-knockout for all ligands 
displayed almost a complete lack of ductal growth into the fat pad at 8-12 weeks (78). In the 
AREG-/- mice, mammary epithelial failed to fill the fat pad even after multiple pregnancies, 
strongly suggesting that AREG-EGFR signaling mediated the impact of estrogen on 
mammary ductal growth. This suggests that EGF and TGF are dispensable for mammary 
gland growth, while AREG plays a vital role in glandular development. Recombination 
grafts indicated that estrogen stimulated pubertal mammary gland growth will not occur 
without AREG signaling to the stroma (79). The AREG gene is regulated by estrogen 
receptor alpha (ER), which apparently accounts for its requirement in postnatal mammary 
gland development (80, 81). Whether there are any ligand specific effects of the AREG 
ligand in mammary development have not been explored. 
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Studies performed with mice deficient for ADAM-17 have shown cardiac insufficiencies, a 
constellation of epithelial defects and die soon after birth similar to the phenotype of EGFR -
/- mice. The ADAM17-/- mice have small, immature mammary glands with minimal 
branching or ductal growth (82). To verify the requirement of ADAM-17, the defective 
growth of ADAM-17-null mammary epithelia can be rescued in the presence of exogenous 
AREG, EGF, or TGF (82). In conclusion, estrogen induced growth of the mammary pad 
requires mammary epithelial cell ADAM-17 to shed AREG which then, is necessary to 
stimulate EGFR signaling in the stromal fibroblasts.  
2.1.2 Breast epithelial stem cell and ErbB signaling  
Potential mammary gland stem and progenitor cells have been identified using a series of 
methodologies used to identify the hierarchy of cells that produces that mature 
hematopoetic system. A single human mammary gland stem cell has been shown to 
regenerate all the cellular components of the human mammary gland, as well as produce 
milk proteins in immunocompromised mice (83-86). This work, coupled with mouse work 
has given rise to an epithelial hierarchy illustrated in figure 2. In this hierarchy, the 
mammary stem cells give rise to “ the common or bipotent” progenitor; the bipotent 
progenitor gives rise to a luminal progenitor, as well as a cell type that gives rise to mature 
myoepthelial cells; and the luminal progenitor produces derivatives that ultimately 
differentiate into mature duct and alveolar cells (83-86). 
The reproducible isolation of stem and progenitor cells from mammary epithelia has 
permitted profiling the various cell types for the expression of the receptors involved in 
post-natal mammary gland growth and breast cancer progression (85). The subpopulation 
containing putative mammary multipotent stem cells appear to lack expression of estrogen 
and progesterone receptors, whereas the EGFR is expressed in ~12% of this fraction. Nearly 
50% of the luminal progenitor inclusive population expressed high levels of EGFR. The 
relatively small subset of the differentiated luminal cell segment (ductal and alveolar cells) 
express the EGFR (83-86). Of possible significance is that both the mammary stem cell and 
luminal progenitor population are routinely propagated in a media supplement containing 
EGF. Whether this implies that propagation of these stem and progenitor cells are 
dependent on EGFR signaling or simply that there is a requirement for generalized receptor 
tyrosine kinase activity remains to be determined. 
Taken together, the post-natal development of the mammary gland is regulated in large part 
by the EGFR. EGFR signaling in stromal fibroblasts is required for the estrogen-stimulated 
invasion mammary epithelium into the stromal fat pad that establishes the adult virgin 
mammary gland. It appears that the stromal EGFR signaling is mediated primarily by the 
estrogen-controlled ligand, AREG. Interestingly, the EGFR and its ligands are expressed 
in the mammary epithelia, but the recombination experiments suggest that autocrine 
receptor activity in this compartment is dispensable for the establishment of the adult 
mammary gland. At this time, it is not clear if autocrine EGFR signaling in a mammary 
epithelial stem or progenitor cells might be required for maintenance of the organ 
throughout adult life.  
2.2 EGFR signaling and cardiac development 
Careful reexamination of the EGFR-/- mice along with observations from the Waved-2 mice 
(these express a mutant form of the receptor with only 10% kinase activity) found defective  
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Fig. 2. Hierarchy of mammary epithelial cells. 
The various cells of the mammary epithelium and their relationships are represented.  To 
the right, is the expression pattern of the various cell surface markers.  Below this is the ErbB 
and ER expression along with breast cancer cell types the various cells are related to.  
cardiac valve morphogenesis and maturation (94, 96). HB-EGF KO mice also exhibit 
defective maturation of cardiac valves, suggesting that this may be the relevant ligand that 
induces EGFR signaling in this process. Also, the HB-EGF-/- cardiac defect was 
phenocopied in the ADAM-17, suggesting that this protease released the ligand during 
cardiac development (97).  
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In the context of cellular behaviors, it appears that the EGFR signaling system plays a role in 
differentiation. In the EGFR, HB-EGF and ADAM-17 KO mice which have hyperplastic 
valves it appears that the impact of this signaling is distinct from a proliferation and 
migration defect observed with the other ErbB knockouts. It is thought that HB-EGF-EGFR 
signaling decreases BMP expression, the factor which drives cardiac valve maturation, and 
hence is a differentiation factor (97).  
2.3 EGFR signaling and nervous system 
In the mouse, EGFR is highly expressed during brain development (E-7 to E-17) and is 
present on multipotent precursors of both neurons and glia, as well as developing astrocytes 
and some neurons (98, 99). The initial reports of the EGFR knockout did not identify a 
nervous system defect. However, reexamination of the KOs with extended post natal 
survival due to breeding of the knockout allele onto other mouse strains was able to identify 
brain defects (98). Among the defects identified were smaller or thinner forebrain regions, 
including the cerebral cortex, olfactory bulb and neocortex (98). Both HB-EGF and TGF are 
expressed in portion of the fore brain during late embryonic and early postnatal life (98, 
100). Modest histological defects were observed in the prefrontal cortex of mice with a 
conditional KO of HB-EGF in the forebrain, and these mice displayed behavior and defects 
in dopamine metabolism that have been observed in schizophrenia (98). 
The defects observed in the forebrain of the EGFR-KO mice appear to result from disruption of 
the cellular interactions required to support neurons. There was substantial neuronal 
apoptosis in the early postnatal forebrain regions affected (98). However, this occurred in 
EGFR-expressing and non-receptor bearing neurons. In addition, there was a delay in the 
appearance of glial fibrulary acidic protein (GFAP) positive astrocytes in the glial limitans and 
white matter tracks of the fore brain. Although EGFR ligands can stimulate both the 
proliferation of astrocytes and recruitment of these cells from multipotent precursor cells, the 
major defect of the knockout mice appears to have a defect in the migration these glial cells 
from germinal centers. It is speculated that the delay in formation of contacts between 
neurons and astrocytes results in a deficiency of trophic support, resulting in neuronal cell 
death in the forebrain (98, 99).  
EGFR expression is high in developing astrocytes, but the receptor is not present in mature 
astrocytes of the healthy adult brain. Upon injury or disease, EGFR expression is up 
regulated in reactive astrocytes (101). Reactive astrocytes lengthen processes produce 
plasma membrane pseudopodia and increase expression GFAP in response to all forms of 
CNS injury or disease (102). Stimulation of the EGFR on reactive astrocytes results in the 
upregulation of motility chemokines and extracellular matrix remodeling genes that are 
likely to contribute to glial scarring (101). Intriguingly, the use of EGFR tyrosine kinase 
inhibitors reduced nerve loss and lead to greater nerve fiber regeneration in optic nerve 
crush a model of a glial scarring (101). Thus, EGFR signaling in astrocytes facilitates 
neuronal survival during development, but receptor activity in reactive astrocytes actually 
contributes to neuron loss in pathologies.  
2.4 EGFR signaling and bone 
Bone phenotypes had not been reported in the original characterization ErbB receptor KO 
mice. However, work on the problem of malignancy-associated hypercalcemia had long 
established that TGF increased the formation of bone resorbing osteoclasts in bone marrow 
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cultures and whole animals (103, 104). The EGFR is expressed on both chondrocytes and cells 
of the osteoblast lineage in animals and humans (105). However, the function of the receptor 
was not established until a human EGFR gene-knockin mouse was created (106). This human 
EGFR transgene had a limited expression in mouse tissues that normally express the receptor, 
probably due to the presence of the Neo gene in the first intron of the construct. The human 
EGFR was expressed in the heart and nervous system and provided a rescue of the murine 
EGFR KO, but the receptor was not expressed in epithelia and bone. The human EGFR 
knockin mice were growth retarded and the skeletal phenotype appeared to be largely due to 
premature hypertrophy of the growth plate cartilages. Although routine histology did not 
reveal defects in the bones, growth of the knockin osteoblasts in vitro resulted in the increased 
formation of calcified nodules, which represent the end point of differentiation for these cells. 
Thus, in both cartilage and bone, EGFR signaling inhibits differentiation and helps maintain 
chondrocytes and osteoblasts in a proliferative state. At this point, it is unknown if any other 
ErbB receptors play a functional role in bone development or physiology.  
Further insight into the role of EGFR in bone resulted from a study of global changes in 
osteoblast gene expression induced by the main serum calcium regulator, PTH. Activation 
of the PTH receptor on osteoblasts rapidly upregulates AREG mRNA expression 10 to 20-
fold, as well as increasing the TGF and HB-EGF ligands (107, 108). In addition, PTH 
signaling induces shedding of ADAM-17 controlled ligands in the kidney (109). Further 
experiments indicated that addition of exogenous AREG to osteoblasts stimulated their 
proliferation. However ligand-EGFR signaling also inhibited osteoblast differentiation and 
dramatically decreased mineralization of osteoblast cell lines. Consistent with the role for 
AREG in stimulating the proliferation of osteoblasts, 4-week-old AREG-knockout mice 
exhibited less trabecular bone in the tibia than wild type littermates (107). These 
experiments suggested that EGFR signaling may mediate the impact of PTH on the 
recruitment and expansion of cells committed to the osteoblast lineage, but excessive 
signaling by this system could prevent these cells from undergoing terminal differentiation 
and forming mineralized bone. The inhibition of osteoblast differentiation and subsequent 
mineralized bone matrix deposition by-EGFR signaling may contribute to the uncoupling of 
bone formation from the accelerated bone resorbtion  
3. EGFR and breast cancer 
3.1 ErbB and EGFR expression in primary tumors  
The development of platforms capable of simultaneously evaluating gene expression from a 
large portion of the genome have lead to identification of gene expression profiles that 
correlate with various established and some novel classes of breast cancer. These profiles 
have produced further insights into the impact of ErbB family members in breast cancer 
progression. Based on these studies, breast cancers are now divided into the following 
subclasses: ErbB2 amplified, luminal A, luminal B, normal breast-like, and basal (110-112). 
The ErbB2 amplified, basal and luminal B subtypes had substantially worse prognosis than 
the normal breast-like and luminal A.  
3.1.1 ErbB2 amplified tumors 
Among the molecular subclasses of breast cancer, the ErbB2 amplified, has the most well 
established functional role for an ErbB member in disease development and progression. 
The ErbB2 amplified tumors typically express ErbB3 and cell line experiments suggest the 
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ErbB2/ErbB3 heterodimers stimulate proliferation of these cells through the PI3 kinase-AKT 
pathway (113). Despite the identification of the ErbB2 co-receptor, the precise ligand 
activating the ErbB3 has not been established. In addition, the correlation between high 
ErbB2 expression and poor prognosis suggests that ErbB2 contributes to metastasis and how 
the receptor contributes to these processes, is still under investigation (110-112). 
3.1.2 ER+ tumors: luminal A&B 
Luminal A tumors express ER along with GATA binding protein 3, X-box binding 
protein 1, trefoil factor 3, and other estrogen-regulated genes and high levels of the 
luminal keratins K8 and 18 (110-112). Luminal B tumors tend to express the above 
markers at slightly reduced levels, but have an upregulated cassette of genes, including 
proliferation related genes such as Myb and components involved in DNA replication. 
There is no specific ErbB family member included in luminal A or B signature. Further 
evaluations of ER+ tumors have indicated that the majority of these tumors lack ErbB2 
and EGFR expression, but close examination of data from microarray and PCR studies 
suggest there are occasional luminal type tumors that express these receptors (16, 110-
112). A large fraction of ER+ tumors also contain ErbB4 (110-112), and there is some 
indication this receptor may be involved in a reciprocal regulatory loop with ER 
signaling (114). Surprisingly, AREG was not in the original gene set that defined ER+ 
luminal tumors. A follow up interrogation of data that was used to relate disease outcome 
to cancer subclasses identified a correlation between higher levels of AREG expression, 
ER, and the luminal A subclass (115). Also, this analysis indicated that ADAM-17 levels 
were low in the luminal A class relative to other tumor subtypes. These observations 
suggest that although most ER+ luminal A breast cancers express AREG, they lack the 
EGFR; therefore, autocrine signaling by this ligand receptor system should not be present 
in most of these tumors. Because the tumor cells express low levels of ADAM-17 it is 
unclear whether AREG could even participate in paracrine signaling between luminal A 
breast cancer cells and the tumor stroma. There is a possibility that other proteases 
produced by the tumor cell or microenvironment lead to shedding of AREG by luminal A 
breast cancers but whether this signaling impacts progression is unclear. 
3.1.3 Normal-like breast cancers 
The gene expression signature of these tumors clustered with the normal breast samples. 
These tumors had a signature that was not associated with epithelial cell types. They instead 
express high levels of collagen receptors, lipoprotein lipase and glycerol-3-phosphate 
dehydrogenase normally found in stromal cells or adipocytes. High levels of AREG and 
moderate levels of ADAM-17 were observed in occasional samples from this group of 
tumors, but the EGFR was absent. At this time there is no evidence that ErbB signaling plays 
any role in the biology of these tumors (110-112). 
3.1.4 Basal tumors 
These tumors lack the expression of the estrogen, progesterone and ErbB2 receptor-for this 
reason they are often called triple receptor negative tumors-and these cancers express some 
markers consistent with the myoepithelial cells that are in contact with the basement 
membrane. These tumors express high levels of the epithelial markers kertatin 5 and 14 
(basal keratins), P cadherin as well as troponin (110-112). Basal breast cancers are correlated 
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with poor survival, high rates of distant metastasis and are generally high grade, large 
tumors. Once the category became established, antibody labeling studies indicated that 50 to 
70% of the basal cancers expressed high levels of EGFR immunoreactivity (116). Low levels 
of EGFR expression is correlated with reduced numbers of distant metastasis (117). These 
tumors also frequently express elevated levels of TGF and ADAM-17 (115).  
Within basal breast cancers there could be a fraction that exhibits autocrine TGF-EGFR 
signaling. The correlation of ADAM-17, TGF and EGFR with poor prognosis implicates 
some role for this signaling system in metastasis. At this time, functional testing of TGF in 
basal breast cancer models has not been completed. One major question that remains is: 
does TGF participate in autocrine tumor cell signaling or paracrine tumor-stroma 
interactions. Future studies will identify which prometastatic cellular behaviors are 
activated by TGF-EGFR signaling, providing insight into whether receptor-targeted 
therapeutics might provide benefit in a metastasis prevention paradigm. 
 
 
Fig. 3. Summary of EGFR-ligand signaling in models of basal breast cancer metastases. 
The specific ligand involved in primary tumors and metastatic site are indicated by the 
colored hexagons. The cell type that responds to the signal is also indicated. Paracrine 
signaling interactions appear to be important to metastases, whereas the relative role of 
autocrine versus paracrine signaling has not been explored in primary basal breast cancer. 
3.2 ErbB signaling in breast cancer metastasis  
Metastasis requires a set of cellular behaviors that are distinct from primary tumor 
formation. To spread from the site of the primary tumor to distant organs cancer cells must: 
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1) move out of the primary tumor and invade through local connective tissue; 2) enter 
capillaries (intravasation); 3) survive in the blood stream; 4) exit the blood stream 
(extravasation) and invade into a new organ; 5) survive in the new organ possibly as a micro 
metastasis; 6) adapt to the new organ and grow as a macrometastasis (virulence) (118, 119). 
These steps can be viewed as two generalized processes: 1) invasion, which is movement of 
cancer cells through normal tissue and entry into the blood stream, and 2) colonization, 
which is escape from the blood stream and growth in a distant organ. Substantial progress is 
being made in identifying metastasis genes that mediate these generalized steps of the 
process. Metastasis genes are thought dispensable for primary tumor initiation and growth, 
but are crucial to the novel processes involved in the spread of cancer (119). In general, 
genes that facilitate invasion for carcinomas such as breast cancer are associated with EMT. 
Some of the genes involved in invasion are expressed in primary tumors. Colonization is 
considered to be the most inefficient part of the metastatic process and the growth of a 
cancer cells in a novel organ is likely to require novel changes in gene expression. Thus, the 
expression of colonization/virulence-associated metastasis genes are thought to be limited 
tumors within the specific target organ, rather than being present in most primary tumors 
(118, 119). Due to less availability, comprehensive gene expression studies of metastases 
have lagged behind the studies of primary tumors. As a result, alternative strategies for 
identifying gene signatures that are functionally involved with metastasis have been 
developed. For breast cancer metastases, Massague and colleagues selected in vitro various 
subclones of the aggressive breast cancer cell line MDA-MB-231. They found that many of 
the subclones had differing capacities to colonize various organs after intracardiac injection 
into mice (12, 119-123). Gene expression profiles were generated from the subclones that 
colonized specific organs, and these were compared to signatures from subclones that 
colonized the other organs. These signatures were then compared to larger data bases 
generated from human primary tumors that had ultimately metastasized to the organ of 
interest producing a refined signature. Subsequent functional analysis of these gene 
signatures has resulted in the identification of specific EGFR ligands as breast cancer 
metastasis genes.  
3.2.1 EREG and lung metastases 
The identification of a lung metastatic signature was derived from subclones of the MDA-
MB-231 (LM) breast cancer cells that produced lesions in the lung after intracardiac 
injection. Among the genes that emerged from this analysis was the ErbB ligand, EREG (121, 
123). Knockdown of EREG alone failed to slow the growth of LM as primary tumors in the 
mammary fat pad or in lung. However, knockdown of EREG in conjunction with 
cyclooxigenase 2 (COX2), MMP1 and MMP2 (these genes had also been identified as 
upregulated in the LM signature) had a dramatic impact on both primary tumor growth and 
subsequent metastasis to lungs. The decreased primary tumor growth in the cells with 
reduced levels of EREG, COX2, MMP1 and MMP2 appeared to result from reduced 
angiogenesis. The LM cells recruited abundant dilated tortuous and leaky blood vessels, and 
the repression of these 4-genes resulted in reduced capillary branching, length and dye 
effusion. However, VEGF levels were not reduced in the quadruple knockdown tumors 
relative to controls. Also, no differences were observed in pericyte recruitment to the 
capillaries between the LM cells and the quadruple knockdowns, suggesting that capillary 
defects were the result of altered endothelial cell behavior. Also, these multiple knockdowns 
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exhibited reduced ability to colonize lungs after intravenous injection as compared to the 
parental LM cells. Close evaluation of the lungs of animals injected with the quadruple 
knockdown cells found abundant cells trapped in the vasculature, suggesting a failure in 
extravasation. The deficiencies in quadruple knockdown extravasation were also observed 
with an in vitro assay. Consistent with the knockdown studies, single therapeutic agents that 
targeted EGFR (such as cetuximab, an EGFR blocking antibody), COX2 (celecoxib) or MMPs 
(GM6001) also had modest impact on behavior of the LM cells grown as primary tumor and 
their spontaneous metastases to the lung. However, combinations of two agents slowed the 
growth of primary tumors and reduced subsequent lung colonization. The efficacy of 
cetuximab suggests that EREG is stimulating this the EGFR and not ErbB4. The fact that LM 
cells lacked upregulation of VEGF production, (an EGFR regulatory target in most cancer 
cells) was interpreted as evidence that EREG functioned in paracrine signaling with 
endothelial cells rather than being engaged in autocrine signaling. 
Although microvasculature defects do not appear to be a major component of the various 
EGFR-/- or other ErbB-knockout mice, studies of normal and tumor capillaries in vitro 
suggest signaling by family members has an influence on angiogenesis. Intriguingly, ErbB 
receptor expression is altered in tumor capillary endothelial cells as compared to those in 
normal vessels. ErbB 2, 3, 4 but minimal EGFR is found in most normal endothelial cells in 
culture (124). In contrast, tumor endothelial cells acquire the EGFR and down regulate 
ErbB3 expression both in vitro and in vivo. Endothelial cells in culture also express EGFR and 
ErbB4 ligands HB-EGF and NRG-1 (124-126). It is thought that HB-EGF signaling through 
both the EGFR and Erbb4 helps recruit pericytes to capillaries to stabilize the structures 
(125). The addition of exogenous EGF to tumor endothelial cells in vitro increases their 
proliferation (124). Shedding of HB-EGF and activation of the EGFR leads to down 
regulation of tight junction proteins and migration of normal endothelial cells (127). Also, 
NRG-1-ErbB4 signaling stimulates endothelial cell proliferation, migration and angiogenesis 
in animals; however, NRG-1 inhibits proliferation of tumor derived endothelial cells (124, 
126). In light of the impact of EGFR signaling on tumor endothelial cells, breast cancer cell 
upregulation of EREG would contribute to the recruitment of a leaky vasculature that is 
common to aggressive tumors. In addition, EREG-EGFR/ErbB4 signaling might contribute 
to intrasavation and extrasavation by down regulation adhesion molecules between 
endothelial cells within capillaries. The question that remains is whether the low affinity 
ligand EREG might be more efficient at stimulating proliferation, migration and 
downregulation of junctional complexes than the high affinity ligand, HB-EGF normally 
present in endothelial cells. 
3.2.2 HB-EGF and brain metastasis 
A brain metastasis signature was derived using methods similar to those described for lung 
metastasis (120, 128). Among the genes that emerged as upregulated in brain metastatic cells 
was the ErbB ligand, HB-EGF (120). Treating mice cardiac-injected with brain seeking 
sublines MDA-MB-231 and CN34-BrM2C with cetuximab resulted in reduced numbers of 
brain metastases. Knockdown of both EREG and HB-EGF, or cetuximab treatment, reduced 
migration of MDA-MB-231 and CN34-BrM2C through consecutive monolayers of 
endothelial cells and astrocytes in a model of blood brain barrier extravasation. Brain 
endothelial cells and astrocytes both express the EGFR (100, 127). Activation of the EGFR 
has been shown to down regulate components of tight junctions in brain endothelial cells 
(127). This coupled with EGFR signaling induced upregulation of motility, chemokines and 
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extracellular matrix remodeling genes in astrocytes would likely aid in extrasavation of 
breast cancer cells through the blood brain barrier into the parenchyma. Beyond this EGFR 
signaling produces reactive astrocytes that are components of the microenvironment of 
brain metastases. This raises the question of whether breast cancer generated EGFR ligands 
could play a role in breast cancer cell virulence in the brain by generating increased 
numbers of reactive astrocytes (129). HB-EGF is the EGFR ligand most abundantly 
expressed in the brain and endothelial cells, suggesting it may be the most well suited 
agonist to mediate in paracrine interactions among cancer cells, capillaries and the brain 
parenchyma. 
3.2.3 AREG and bone metastasis 
Tumor cell colonization of bone may be a less complex process than that of lung and brain 
because the capillaries in bone called sinusoids, have large openings in them to facilitate 
entrance of bone marrow derivatives into the circulation (119). It is thought that cancer cells 
may be able to exit through these openings dispensing with the intricacies of extravasation 
from continuous capillaries.  
The growth of breast cancer macrometastases is described as a vicious cycle (130, 131). In 
this cycle, breast cancer cells exploit the natural renewal process based on the paracrine 
interactions between the bone forming osteoblast and the bone resorbing osteoclast. In 
normal bone, osteoblasts regulate osteoclast numbers and activity by releasing chemokines 
that recruit osteoclast precursors and then differentiate and activate them with a cell surface 
ligand for the receptor for activation of NFκβ (RANKL). Osteoblasts also produce a soluble 
decoy receptor osteoprotegrin (OPG) that prevents RANKL from engaging its receptor; 
therefore, the level of the ratio of OPG to RANKL controls osteoclastogenesis. Once 
activated, osteoclasts adhere to the bone surface and secrete proteases and acid that 
degrades mineralized matrix. Growth factors including TGFβ and IGF-1 are released from 
the bone matrix, and this in turn stimulates new bone matrix formation by osteoblasts. This 
is a regenerating system that is in balance within the local environment; however, the rate of 
turnover and formation can be modulated by a series of endocrine hormones including PTH 
and calcitonin. Within the bone marrow, breast cancer cells produce a series of cytokines 
and growth factors including IL-11 and PTH-related protein (PTHrP) that increase the levels 
of RANKL relative to OPG leading to increased osteoclastogenesis. The increased bone 
resorption and resulting high level of growth factors enhance the survival of breast cancer 
cells, and also TGFβ increases gene expression of IL-11 and PTHrP, which begets more 
osteoclasts.  
Profiling bone metastasis subclones of MDA-MB-231 cells resulted in an 11-gene signature 
(122). Several of the genes identified were factors like IL-11 that directly altered the 
RANKL/OPG ratio or connective tissue factor that enhanced osteoblast proliferation. 
Ectopic expression of a single gene from the profile had very little impact on the ability of 
modestly osteolytic 231 subclones to grow within in the bone of immunocompromised mice. 
However, the combination of 3 of the genes from the signature induced destructive growth 
in bone after intracardiac injection. Among the genes identified in the signature that 
produced increased osteolysis when overexpressed as part of a 3 gene cassette were the 
proteases, MMP1 and ADAMTS-1 (12). It was unclear what the role of these molecules 
would play in bone metastasis. Eventually, a careful evaluation of aggressively osteolytic 
MDA-MB-231 lines that were engineered to overexpress ADAMTS-1 and MMP1 were found 
to shed dramatically increased levels of AREG. Conditioned media from the ADAMTS-1 
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and MMP1 engineered MDA-MB-231 lines caused an increased RANKL/OPG ratio in 
primary murine bone cell cultures (12, 132). The conditioned media from the MDA-MB-231-
ADAMTS-1 and MMP1 cells activated osteoclastogenesis in the primary bone cell cultures, 
and this could be inhibited by the EGFR inhibitors gefitinib or cetuximab. Remarkably, these 
agents (Gefitinib 100mg/kg daily or Cetuximab 100 mg/kg weekly) completely prevented 
the formation of osteolytic lesions by the MDA-MB-231 ADAMTS-1+MMP1 line delivered 
by either the intracardiac or intratibial injection method (12). These findings clearly support 
the notion that EGFR signaling on cells of the osteoblast is a major regulator of the 
RANKL/OPG ratio, but point out the requirement for appropriate protease expression to 
make EGFR ligands accessible to the bone microenvironment. These experiments provide an 
explanation of how bone resorbtion could be uncoupled from bone formation by breast 
cancer cells because stimulation of the EGFR should block osteoblast differentiation and 
matrix production.  
To some extent, the identification of a role for AREG in bone metastasis is confounding 
given that its expression is associated with ER+ breast cancers that generally have good 
prognosis (115). The MDA-MB-231 cells are ER- and have a phenotype that is similar to 
basal cancers. So we interrogated the breast cancer transcriptome datasets GSE2034(133), 
GSE2603 (123), and GSE12276 (120) from the NCBI Gene Expression Omnibus to evaluate 
AREG expression in ER- tumors. We found that AREG expression was lower in the ER-
negative tumors that ultimately metastasized to bone as compared to those that did not 
(134). A similar pattern of expression has been reported for the classical bone metastasis 
virulence factor PTHrP. Low expression of the peptide is observed in the primary tumors 
that ultimately metastasize to bone (135-137). PTHrP gene expression is thought to be 
activated by TGF when breast cancer cells enter the bone microenvironment (138). In 
contrast to PTHrP, the enhanced activity or expression of the proteases that cleave AREG 
would be sufficient to increase its expression in the bone microenvironment without 
activating gene expression. Consistent with this concept, high expression ADAMTS-1 and 
MMP1 protein have been observed in primary breast cancer tumors that ultimately 
metastasized to bone (12). Thus, the complex post-genomic regulation of EGFR ligand 
processing and receptor interactions provides mechanism beyond transcription where the 
amplitude of signaling of this system can be increased to contribute to colonization. Given 
that AREG appears to be the physiological mediator of EGFR signaling in the bone, it may 
be ideally suited to uncouple bone formation from bone resorbtion, which is a component of 
osteolytic predominant bone metastases that arise from breast cancers.  
3.3 Conclusions: EGFR ligand function in breast cancer 
EGFR ligands and receptors are frequently expressed together on epithelial cells and the 
cancers that are derived from these tissues, including the breast. Addition of exogenous 
EGFR ligands to breast epithelial or cancer cells typically has a profound impact on 
proliferation or migratory behavior, leading to the concept that autocrine receptor signaling 
would contribute to tumor progression. Despite this perspective, the unraveling of the 
developmental breast, heart and brain phenotypes of the various family member KOs 
suggest that EGFR, ligand and ADAM-17 function as part of a complex paracrine-signaling 
network. In addition, in vitro and in vivo models based on MDA-MB-231 cells where EGFR 
ligands have been found to function as metastasis genes, suggest they signal in a paracrine 
fashion to key elements of the microenvironment. On the basis of these conclusions, we 
www.intechopen.com
 
Breast Cancer – Carcinogenesis, Cell Growth and Signalling Pathways 
 
22
speculate that TGF expression in primary basal breast cancers may also be engaged in 
paracrine signaling with cells in the microenvironment. This conclusion suggests that the 
efficacy of EGFR targeted therapeutics will depend upon their uses in combination with 
other compounds that target the tumor microenvironment in primary basal tumors, as well 
as those that have metastasized to the lung, brain and bone. 
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